Suppr超能文献

肝移植中存在的门静脉血栓形成:术前疾病严重程度的影响。

Pre-existent portal vein thrombosis in liver transplantation: influence of pre-operative disease severity.

机构信息

Klinik und Poliklinik für Chirurgie, Uniklinikum Regensburg, Regensburg, Germany.

出版信息

Clin Transplant. 2010 Jan-Feb;24(1):48-55. doi: 10.1111/j.1399-0012.2009.00977.x. Epub 2009 Feb 19.

Abstract

BACKGROUND

Portal vein thrombosis (PVT) is a surgical challenge in liver transplantation (LTx). In contrast to LTx in decompensated liver disease, which are associated with a higher morbidity and mortality, PVT influence on outcome is still under debate. To evaluate this influence at different stages of liver decompensation, we compared the outcome of patients suffering from PVT to patients with patent portal vein within different score ranges.

METHODS

We included 193 LTx (24 with PVT) in our study, transplanted between 2004 and 2007 at our institution. Patients were divided into four Model of End-Stage Liver Disease (MELD) score groups, and outcome was compared between PVT- and non-PVT patients.

RESULTS

In non-decompensated liver disease (MELD <15), we found a significantly decreased survival in patients suffering from PVT (one-yr survival 57% vs. 89%). By contrast, MELD score >15 (decompensated liver disease) leads to an equal or even better survival in PVT-patients compared with patients without PVT (one-yr survival 91% vs.75%), with an only slightly increased morbidity.

CONCLUSION

Outcome in patients with PVT seems to be dependent on pre-operative disease severity. In contrast to compensated liver disease, no influence of PVT on outcome could be found in decompensated liver disease, and should therefore not be considered as a contraindication in LTx.

摘要

背景

门静脉血栓形成(PVT)是肝移植(LTx)中的一个手术挑战。与失代偿性肝病相关的 LTx 相比,其发病率和死亡率更高,而 PVT 对预后的影响仍存在争议。为了在不同的肝失代偿阶段评估这种影响,我们比较了患有 PVT 的患者与门静脉通畅的患者在不同评分范围内的结局。

方法

我们纳入了本机构在 2004 年至 2007 年间进行的 193 例 LTx(其中 24 例有 PVT)。患者被分为四个终末期肝病模型(MELD)评分组,并比较 PVT 患者与非 PVT 患者的结局。

结果

在非代偿性肝病(MELD<15)中,我们发现患有 PVT 的患者生存率显著降低(1 年生存率为 57%对 89%)。相比之下,MELD 评分>15(失代偿性肝病)导致 PVT 患者的生存率与无 PVT 患者相当,甚至更好(1 年生存率为 91%对 75%),且发病率仅略有增加。

结论

PVT 患者的结局似乎取决于术前疾病的严重程度。与代偿性肝病相反,在失代偿性肝病中,PVT 对结局没有影响,因此不应将其视为 LTx 的禁忌证。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验